11.5 C
New York
Wednesday, February 8, 2023

Is There Anything That This Pre-Hours Session Is Boosting For Lucira Health (LHDX) Stock?

Following getting approval, Lucira Health Inc. (NASDAQ: LHDX) is soaring on the charts today, up 20.49% to trade at $0.4799 at the most recent check in premarket activity.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Which go ahead has LHDX gotten?

The Lucira COVID-19 & Flu Test has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for point-of-care usage, according to Lucira Health (LHDX). In clinical studies, the Lucira COVID-19 & Flu Test performed similarly to extremely sensitive lab-based PCR testing. This combination test is the first in a pipeline of additional multiple assay tests that make use of the multiplexing capabilities of the Lucira technology platform from a single sample. One shallow nose swab for the simple test yields findings in between 11 and 30 minutes.

Antigen COVID-19 assays are inaccurate, making them unsuitable for use in the early differential diagnosis of flu vs COVID-19. Clinicians may now organize mass simultaneous fast testing in order to put patients on the road to recovery as soon as possible. With the results of this test and upcoming testing capabilities, LHDX hopes to lead the way in effective at-home health management.

LHDX started an online program:

Lucira Connect, a new virtual care program from LHDX, was just released. It offers Lucira test users the ability to test, learn about treatment options, access a telehealth consultation, and, if necessary, receive a prescription, all from the comfort of their own homes, for just $29 (excluding prescription costs) for the test itself.

Nationally accessible Lucira Connect is a user-friendly web-based platform that starts with self-administration of the company’s straightforward at-home molecular COVID-19 test. Users may capture their test results with their smartphone and receive 98% accurate findings in less than 30 minutes. Users will have the opportunity to receive a virtual telemedicine consultation to talk about their risk factors and suitable treatment choices with an impartial medical expert if the test for COVID-19 is positive.

What else is LHDX doing?

Lucira Health (LHDX) and Pfizer Inc. are working together to spread knowledge about the dangers of COVID-19 and the range of available treatments. To help LHDX test consumers understand their risk of progression to severe COVID-19, Pfizer is creating educational and risk assessment tools that will be accessible on Lucira Connect.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles